[EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET MÉTHODES
申请人:TEMPERO PHARMACEUTICALS INC
公开号:WO2013019621A1
公开(公告)日:2013-02-07
The present invention relates to novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.
本发明涉及新型视黄醛酸相关孤儿受体γ(RORγ)调节剂及其在治疗由RORγ介导的疾病中的应用。
[EN] ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS<br/>[FR] COMPOSÉS OLÉFINIQUES À SUBSTITUTION ARYLE EN TANT QU'INHIBITEURS DE LA PDE10A
申请人:GLENMARK PHARMACEUTICALS SA
公开号:WO2011138657A1
公开(公告)日:2011-11-10
The present invention provides aryl substituted olefinic compounds as Phosphodiesterase 1 0A (PDE 1 0A) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phosphodiesterase 1 0A enzyme. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof.
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
本发明涉及新型视黄醇相关孤儿受体伽玛(RORγ)调节剂及其在治疗由RORγ介导的疾病中的应用。
Structure–Activity Relationship Studies of the Aryl Acetamide Triazolopyridazines against <i>Cryptosporidium</i> Reveals Remarkable Role of Fluorine
作者:Tanner J. Schubert、Edmund Oboh、Hannah Peek、Emily Philo、José E. Teixeira、Erin E. Stebbins、Peter Miller、Jonathan Oliva、Francis M. Sverdrup、David W. Griggs、Christopher D. Huston、Marvin J. Meyers